Digital endpoints, particularly those based on passive monitoring, enable the capture of meaningful, regulatory-relevant data from the daily life of patients. They are playing an increasingly important role in drug validation, with numerous pharmaceutical and biotech companies including them in the design of their trials.
However, including a digital endpoint and its associated technology and processes in a clinical trial is not without consequences on the conduct of the trial and beyond.
In this white paper, we propose a decision-making support tool to help clinical development teams form a clearer picture of the impacts of digital endpoint selection for their trials.
Download our free white paper here!
